Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey.
Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey.
复制标题
DOI：
10.1136/rmdopen-2022-002587
复制
发表时间：
2022-09
期刊：
影响因子：
6.2
通讯作者：
Sparks, Jeffrey A.
中科院分区：
文献类型：
--
作者：
DiIorio, Michael;Kennedy, Kevin;Liew, Jean W.;Putman, Michael S.;Sirotich, Emily;Sattui, Sebastian E.;Foster, Gary;Harrison, Carly;Larche, Maggie J.;Levine, Mitchell;Moni, Tarin T.;Thabane, Lehana;Bhana, Suleman;Costello, Wendy;Grainger, Rebecca;Machado, Pedro M.;Robinson, Philip C.;Sufka, Paul;Wallace, Zachary S.;Yazdany, Jinoos;Gore-Massy, Monique;Howard, Richard A.;Kodhek, More A.;Lalonde, Nadine;Tomasella, Laura-Ann;Wallace, John;Akpabio, Akpabio;Alpizar-Rodriguez, Deshire;Beesley, Richard P.;Berenbaum, Francis;Bulina, Inita;Chock, Eugenia Yupei;Conway, Richard;Duarte-Garcia, Ali;Duff, Eimear;Gheita, Tamer A.;Graef, Elizabeth R.;Hsieh, Evelyn;El Kibbi, Lina;Liew, David F. L.;Lo, Chieh;Nudel, Michal;Singh, Aman Dev;Singh, Jasvinder A.;Singh, Namrata;Ugarte-Gil, Manuel F.;Hausmann, Jonathan S.;Simard, Julia F.;Sparks, Jeffrey A.
我们调查了全身性自身免疫性风湿病（SARD）患者中COVID-19症状持续时间延长的情况，定义为持续28天或更长时间。我们分析了COVID-19全球流变学联盟疫苗调查（2021年4月2日至2021年10月15日）的数据，以识别报告经测试确诊的COVID-19的SARD患者。参与者报告了COVID-19的严重程度和症状持续时间、社会人口统计学和临床特征。我们报告了症状持续时间延长的比例，并使用logistic回归研究了与基线特征的相关性。我们确定了441名SARD和COVID-19患者（平均年龄48.2岁，83.7%为女性，39.5%为类风湿性关节炎）。中位COVID-19症状持续时间为15天（IQR 7，25）。总体而言，107名（24.2%）受访者的症状持续时间延长（≥ 28天）; 42/429名（9.8%）报告症状持续≥ 90天。与症状持续时间延长几率较高相关的因素包括：因COVID-19住院vs未住院和轻度急性症状（年龄校正OR（aOR）6.49，95% CI 3.03 - 14.1）、合并症计数（aOR 1.11/合并症，95% CI 1.02 - 1.21）和骨关节炎（aOR 2.11，95% CI 1.01 - 4.27）。与2020年6月或更早时间相比，2021年发生的COVID-19与症状持续时间延长的可能性较低相关（aOR 0.42，95%CI 0.21至0.81）。大多数SARD患者在COVID-19发病后第15天症状完全缓解。然而，约四分之一的人经历了28天或更长的COVID-19症状;十分之一的人经历了90天或更长的症状。未来的研究需要调查免疫调节药物、SARD类型/发作、疫苗剂量和新型病毒变异与SARD患者中COVID-19症状延长和其他COVID-19急性后后遗症之间的可能关系。
We investigated prolonged COVID-19 symptom duration, defined as lasting 28 days or longer, among people with systemic autoimmune rheumatic diseases (SARDs). We analysed data from the COVID-19 Global Rheumatology Alliance Vaccine Survey (2 April 2021–15 October 2021) to identify people with SARDs reporting test-confirmed COVID-19. Participants reported COVID-19 severity and symptom duration, sociodemographics and clinical characteristics. We reported the proportion experiencing prolonged symptom duration and investigated associations with baseline characteristics using logistic regression. We identified 441 respondents with SARDs and COVID-19 (mean age 48.2 years, 83.7% female, 39.5% rheumatoid arthritis). The median COVID-19 symptom duration was 15 days (IQR 7, 25). Overall, 107 (24.2%) respondents had prolonged symptom duration (≥28 days); 42/429 (9.8%) reported symptoms lasting ≥90 days. Factors associated with higher odds of prolonged symptom duration included: hospitalisation for COVID-19 vs not hospitalised and mild acute symptoms (age-adjusted OR (aOR) 6.49, 95% CI 3.03 to 14.1), comorbidity count (aOR 1.11 per comorbidity, 95% CI 1.02 to 1.21) and osteoarthritis (aOR 2.11, 95% CI 1.01 to 4.27). COVID-19 onset in 2021 vs June 2020 or earlier was associated with lower odds of prolonged symptom duration (aOR 0.42, 95% CI 0.21 to 0.81). Most people with SARDs had complete symptom resolution by day 15 after COVID-19 onset. However, about 1 in 4 experienced COVID-19 symptom duration 28 days or longer; 1 in 10 experienced symptoms 90 days or longer. Future studies are needed to investigate the possible relationships between immunomodulating medications, SARD type/flare, vaccine doses and novel viral variants with prolonged COVID-19 symptoms and other postacute sequelae of COVID-19 among people with SARDs.
登录
查看更多内容
影响因子：
3.1
作者：
Leon L;Perez-Sancristobal I;Madrid A;Lopez-Pedraza L;Colomer JI;Lerma S;Lois P;Mucientes A;Rodriguez-Rodriguez L;Fernandez-Gutierrez B;Abasolo L
通讯作者：
Abasolo L
DOI：
10.1056/nejmoa2022926
发表时间：
2020-11-19
期刊：
The New England journal of medicine
影响因子：
--
作者：
RECOVERY Collaborative Group;Horby P;Mafham M;Linsell L;Bell JL;Staplin N;Emberson JR;Wiselka M;Ustianowski A;Elmahi E;Prudon B;Whitehouse T;Felton T;Williams J;Faccenda J;Underwood J;Baillie JK;Chappell LC;Faust SN;Jaki T;Jeffery K;Lim WS;Montgomery A;Rowan K;Tarning J;Watson JA;White NJ;Juszczak E;Haynes R;Landray MJ
通讯作者：
Landray MJ
COVID-19 的 50 多种长期影响：系统回顾和荟萃分析。
影响因子：
4.6
作者：
Lopez-Leon S;Wegman-Ostrosky T;Perelman C;Sepulveda R;Rebolledo PA;Cuapio A;Villapol S
通讯作者：
Villapol S
影响因子：
5
作者：
Di Iorio, Michael;Cook, Claire E.;Vanni, Kathleen M. M.;Patel, Naomi J.;D'Silva, Kristin M.;Fu, Xiaoqing;Wang, Jiaqi;Prisco, Lauren C.;Kowalski, Emily;Zaccardelli, Alessandra;Martin, Lily W.;Qian, Grace;Hsu, Tiffany Y-T;Wallace, Zachary S.;Sparks, Jeffrey A.
通讯作者：
Sparks, Jeffrey A.
DOI：
10.1056/nejmoa2109072
发表时间：
2021-10-14
期刊：
The New England journal of medicine
影响因子：
--
作者：
Bergwerk M;Gonen T;Lustig Y;Amit S;Lipsitch M;Cohen C;Mandelboim M;Levin EG;Rubin C;Indenbaum V;Tal I;Zavitan M;Zuckerman N;Bar-Chaim A;Kreiss Y;Regev-Yochay G
通讯作者：
Regev-Yochay G